Precise quantitation of 136 urinary proteins by LC/MRM-MS using stable isotope labeled peptides as internal standards for biomarker discovery and/or verification studies
[Display omitted] •Most multiplexed and broadest protein panel quantified via MRM with SIS peptides.•The 136 quantified urinary proteins span >5 orders of magnitude in concentration.•Quantitative reproducibility of 8.6% CV, on average, from a process triplicate.•Largest panel to date can serve as...
Gespeichert in:
Veröffentlicht in: | Methods (San Diego, Calif.) Calif.), 2015-06, Vol.81, p.24-33 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [Display omitted]
•Most multiplexed and broadest protein panel quantified via MRM with SIS peptides.•The 136 quantified urinary proteins span >5 orders of magnitude in concentration.•Quantitative reproducibility of 8.6% CV, on average, from a process triplicate.•Largest panel to date can serve as a guide in biomarker assessment studies.
Spurred on by the growing demand for panels of validated disease biomarkers, increasing efforts have focused on advancing qualitative and quantitative tools for more highly multiplexed and sensitive analyses of a multitude of analytes in various human biofluids. In quantitative proteomics, evolving strategies involve the use of the targeted multiple reaction monitoring (MRM) mode of mass spectrometry (MS) with stable isotope-labeled standards (SIS) used for internal normalization. Using that preferred approach with non-invasive urine samples, we have systematically advanced and rigorously assessed the methodology toward the precise quantitation of the largest, multiplexed panel of candidate protein biomarkers in human urine to date. The concentrations of the 136 proteins span >5 orders of magnitude (from 8.6μg/mL to 25pg/mL), with average CVs of 8.6% over process triplicate. Detailed here is our quantitative method, the analysis strategy, a feasibility application to prostate cancer samples, and a discussion of the utility of this method in translational studies. |
---|---|
ISSN: | 1046-2023 1095-9130 |
DOI: | 10.1016/j.ymeth.2015.04.001 |